New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care
01 Novembro 2023 - 10:00AM
Business Wire
Studies reinforce the influence of new
technology on effective, efficient kidney care
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical
technology company reducing the cost and complexity of dialysis
with its Tablo® Hemodialysis System, today announced significant
data findings on how the use of Tablo increases racial diversity
among users, enhances patient outcomes in the Medicare
fee-for-service population, and notably decreases hospital
transfers in rural Alaskan communities.
The five abstracts will be showcased at the American Society of
Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs
November 2-5. The annual event gathers more than 10,000 kidney care
professionals from across the globe, offering a forum to delve into
the latest advancements in nephrology and to collaborate on kidney
care innovation.
"The research abstracts we're presenting at ASN Kidney Week are
more than data points; they are a testament to Tablo's
adaptability, versatility and its profound impact on equitable
healthcare,” said Michael Aragon, MD, Chief Medical Officer of
Outset Medical. “We're shining a spotlight on the concrete
solutions that our data has revealed, solutions that transcend
barriers in user diversity, Medicare adoption, rural healthcare and
more.”
Notable Abstracts & Findings:
- Characteristics of the First 500 Tablo Home Hemodialysis
(HHD) Users – This retrospective analysis showcases a slightly
older and more racially diverse demographic, underscoring the
importance of achieving equity across all demographic strata for
successful home adoption in the U.S.
- Characteristics of Tablo Home Hemodialysis Users in Medicare
Fee-For-Service – This early look at Tablo HHD patients in the
Medicare fee-for-service population reveals a diverse,
catheter-dependent patient group, illuminating a path toward a more
inclusive future for kidney care.
- Patient-Reported Outcomes (PRO) among Patients Receiving
Home Hemodialysis – In this prospective study of 57 patients
using Tablo for HHD, preliminary results reveal improved
self-reported physical health and reduced symptoms of insomnia,
underscoring the positive impact of Tablo-enabled home dialysis on
patients' well-being.
- Rural Alaskan Experience Insourcing Innovative Dialysis
Technology – A case study in rural Alaska shows a marked
decrease in hospital transfers and exceptional outcomes since the
implementation of Tablo, exemplifying its potential to increase
patient access and elevate kidney care in underserved areas. Only a
single patient was transferred for care since implementation,
versus 71 in the prior year.
- Designing Memorability and Learnability into Dialysis:
Extended Training Decay Periods in a Human Factors Evaluation of
the Tablo Hemodialysis System – A human factors evaluation
underscores the ease of use and memorability of Tablo for both
healthcare providers and patient/care partner pairs, even after
extended training decay periods of up to 28 days.
“Outset's latest research underscores a transformative shift in
kidney care, one that points toward patient-centered care, and
broadened access to home dialysis in underserved and remote areas,”
said Leslie Trigg, Chair and Chief Executive Officer of Outset.
“We’re pushing the boundaries of what's possible in kidney care to
create a better option for providers and patients.”
The studies can be read in their entirety on the clinical
evidence page of the Outset Medical website. Attendees are invited
to visit the Outset booth (#1117) during the ASN meeting for more
information.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a
first-of-its-kind technology to reduce the cost and complexity of
dialysis. The Tablo Hemodialysis System, FDA-cleared for use from
the hospital to the home, represents a significant technological
advancement that transforms the dialysis experience for patients
and operationally simplifies it for providers. Tablo serves as a
single enterprise solution that can be utilized across the
continuum of care, allowing dialysis to be delivered anytime,
anywhere and by anyone. The integration of water purification and
on-demand dialysate production enables Tablo to serve as a dialysis
clinic on wheels, with 2-way wireless data transmission and a
proprietary data analytics platform powering a new holistic
approach to dialysis care. Tablo is a registered trademark of
Outset Medical, Inc.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include statements regarding Outset’s
beliefs, projections and expectations concerning, among other
things, the potential impact of the research results discussed in
this press release. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be
predicted or quantified, which could cause actual results and other
events to differ materially from those expressed or implied in such
statements. These risks and uncertainties include risks described
in the Risk Factors section of Outset’s public filings with the
U.S. Securities and Exchange Commission, including its latest
annual and quarterly reports. These forward-looking statements
speak only as of the date hereof and should not be unduly relied
upon. Outset disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101481362/en/
Nicole Shannon Director, Marketing Communications for Outset
Medical nshannon@outsetmedical.com
Jim Mazzola Vice President, Investor Relations for Outset
Medical jmazzola@outsetmedical.com
Outset Medical (NASDAQ:OM)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Outset Medical (NASDAQ:OM)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024